A common GSAP promoter variant contributes to Alzheimer's disease liability

Neurobiology of Aging

Volumn 35, Issue 11, 2014, Pages 2656.e1-2656.e7

  Zhu, Min ^a   Tao, Yu ^a   He, Qin ^a   Gao, Hui ^a   Song, Fan ^a   Sun, Yi Min ^a   Li, Hong Lei ^a   Wu, Zhi Ying ^a   Saffen, David ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Association study; Expression quantitative trait locus (eQTL); Secretase activating protein (gSAP)

Indexed keywords

APOLIPOPROTEIN E4; GAMMA SECRETASE; GAMMA SECRETASE ACTIVATING PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; GAMMA-SECRETASE ACTIVATING PROTEIN, HUMAN; PROTEIN;

ALLELE; ALZHEIMER DISEASE; APOE4 GENE; ARTICLE; CASE CONTROL STUDY; CAUCASIAN; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GSAP GENE; HAN CHINESE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPORAL CORTEX; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MALE; METABOLISM; RISK; SAMPLE SIZE; TEMPORAL LOBE;

ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEINS; RISK; RNA, MESSENGER; SAMPLE SIZE; TEMPORAL LOBE;

EID: 84922896421     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.05.018     Document Type: Article

References (31)

1. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
2. Boyle A.P., Hong E.L., Hariharan M., Cheng Y., Schaub M.A., Kasowski M., Karczewski K.J., Park J., Hitz B.C., Weng S., Cherry J.M., Snyder M. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012, 22:1790-1797.
3. Chang W.C., Hung J.J. Functional role of post-translational modifications of Sp1 in tumorigenesis. J.Biomed. Sci. 2012, 19:94.
4. Chen L.H., Kao P.Y., Fan Y.H., Ho D.T., Chan C.S., Yik P.Y., Ha J.C., Chu L.W., Song Y.Q. Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer's disease in a southern Chinese population. Neurobiol. Aging 2012, 33:e211-e217.
5. Colantuoni C., Lipska B.K., Ye T., Hyde T.M., Tao R., Leek J.T., Colantuoni E.A., Elkahloun A.G., Herman M.M., Weinberger D.R., Kleinman J.E. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature 2011, 478:519-523.
6. Dynan W.S., Tjian R. Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. Cell 1983, 32:669-680.
7. Dynan W.S., Tjian R. The promoter-specific transcription factor Sp1 binds to upstream sequences in the SV40 early promoter. Cell 1983, 35:79-87.
8. Garcia-Huerta P., Diaz-Hernandez M., Delicado E.G., Pimentel-Santillana M., Miras-Portugal M.T., Gomez-Villafuertes R. The specificity protein factor Sp1 mediates transcriptional regulation of P2X7 receptors in the nervous system. J.Biol. Chem. 2012, 287:44628-44644.
9. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
10. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
11. He G., Luo W., Li P., Remmers C., Netzer W.J., Hendrick J., Bettayeb K., Flajolet M., Gorelick F., Wennogle L.P., Greengard P. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 2010, 467:95-98.
12. Howie B.N., Donnelly P., Marchini J. Aflexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009, 5:e1000529.
13. Jun G., Naj A.C., Beecham G.W., Wang L.S., Buros J., Gallins P.J., Buxbaum J.D., Ertekin-Taner N., Fallin M.D., Friedland R., Inzelberg R., Kramer P., Rogaeva E., St George-Hyslop P., Cantwell L.B., Dombroski B.A., Saykin A.J., Reiman E.M., Bennett D.A., Morris J.C., Lunetta K.L., Martin E.R., Montine T.J., Goate A.M., Blacker D., Tsuang D.W., Beekly D., Cupples L.A., Hakonarson H., Kukull W., Foroud T.M., Haines J., Mayeux R., Farrer L.A., Pericak-Vance M.A., Schellenberg G.D. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch. Neurol. 2010, 67:1473-1484.
14. Lee J.H., Cheng R., Graff-Radford N., Foroud T., Mayeux R. Analyses of the National Institute on Aging late-onset Alzheimer's disease family study: implication of additional loci. Arch. Neurol. 2008, 65:1518-1526.
15. Li H., Wetten S., Li L., St Jean P.L., Upmanyu R., Surh L., Hosford D., Barnes M.R., Briley J.D., Borrie M., Coletta N., Delisle R., Dhalla D., Ehm M.G., Feldman H.H., Fornazzari L., Gauthier S., Goodgame N., Guzman D., Hammond S., Hollingworth P., Hsiung G.Y., Johnson J., Kelly D.D., Keren R., Kertesz A., King K.S., Lovestone S., Loy-English I., Matthews P.M., Owen M.J., Plumpton M., Pryse-Phillips W., Prinjha R.K., Richardson J.C., Saunders A., Slater A.J., St George-Hyslop P.H., Stinnett S.W., Swartz J.E., Taylor R.L., Wherrett J., Williams J., Yarnall D.P., Gibson R.A., Irizarry M.C., Middleton L.T., Roses A.D. Candidate single-nucleotide polymorphisms from a genome-wide association study of Alzheimer disease. Arch. Neurol. 2008, 65:45-53.
16. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J.Natl. Cancer Inst. 1959, 22:719-748.
17. Marchini J., Howie B., Myers S., McVean G., Donnelly P. Anew multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 2007, 39:906-913.
18. Mittal V.A., Walker E.F. Diagnostic and statistical manual of mental disorders. Psychiatry Res. 2011, 189:158-159.
19. Pickrell J.K., Marioni J.C., Pai A.A., Degner J.F., Engelhardt B.E., Nkadori E., Veyrieras J.B., Stephens M., Gilad Y., Pritchard J.K. Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature 2010, 464:768-772.
20. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
21. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N.Engl. J. Med. 2010, 362:329-344.
22. Reiman E.M., Webster J.A., Myers A.J., Hardy J., Dunckley T., Zismann V.L., Joshipura K.D., Pearson J.V., Hu-Lince D., Huentelman M.J., Craig D.W., Coon K.D., Liang W.S., Herbert R.H., Beach T., Rohrer K.C., Zhao A.S., Leung D., Bryden L., Marlowe L., Kaleem M., Mastroeni D., Grover A., Heward C.B., Ravid R., Rogers J., Hutton M.L., Melquist S., Petersen R.C., Alexander G.E., Caselli R.J., Kukull W., Papassotiropoulos A., Stephan D.A. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007, 54:713-720.
23. Robins J., Breslow N., Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 1986, 42:311-323.
24. Schaub M.A., Boyle A.P., Kundaje A., Batzoglou S., Snyder M. Linking disease associations with regulatory information in the human genome. Genome Res. 2012, 22:1748-1759.
25. Sleegers K., Lambert J.C., Bertram L., Cruts M., Amouyel P., Van Broeckhoven C. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet. 2010, 26:84-93.
26. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A 1993, 90:1977-1981.
27. van der Flier W.M., Pijnenburg Y.A., Fox N.C., Scheltens P. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE varepsilon4 allele. Lancet Neurol. 2011, 10:280-288.
28. Wijsman E.M., Pankratz N.D., Choi Y., Rothstein J.H., Faber K.M., Cheng R., Lee J.H., Bird T.D., Bennett D.A., Diaz-Arrastia R., Goate A.M., Farlow M., Ghetti B., Sweet R.A., Foroud T.M., Mayeux R. Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet. 2011, 7:e1001308.
29. Willer C.J., Li Y., Abecasis G.R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010, 26:2190-2191.
30. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Nordberg A., Backman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., de Leon M., DeCarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Jack C., Jorm A., Ritchie K., van Duijn C., Visser P., Petersen R.C. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J.Intern. Med. 2004, 256:240-246.
31. Xu X., Wang H., Zhu M., Sun Y., Tao Y., He Q., Wang J., Chen L., Saffen D. Next-generation DNA sequencing-based assay for measuring allelic expression imbalance (AEI) of candidate neuropsychiatric disorder genes in human brain. BMC Genomics 2011, 12:518.